Wednesday, July 8, 2026

Patent intelligence · US

US 10793543

Selective C-KIT kinase inhibitor

granted A61KA61K31/445A61K31/45A61K31/454
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 34
Patent details — US 10793543
Jurisdiction
US
Status
granted
Grant date
Oct 6, 2020
Expiration
Oct 1, 2040
Claims
8
CPC classes
A61K, A61K31/445, A61K31/45, A61K31/454
View on Google Patents ↗

Quick answer

US 10793543 (Selective C-KIT kinase inhibitor) is held by HEFEI GRACEVO BIO-MEDICINE CO., LTD. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K31/445, A61K31/45, A61K31/454, A61K31/4545, A61P

More from HEFEI GRACEVO BIO-MEDICINE CO., LTD

Related pharmaceutical patents in our USPTO index.

  1. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. · Expires Sep 11, 2045

    granted
  2. US 12049487

    Universal chimeric antigen receptor T-cell preparation technique

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Expires Jul 25, 2044

    granted
  3. US 11840575

    Engineered immune cells targeting BCMA and their uses thereof

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Expires Dec 7, 2043

    granted
  4. US 11484501

    Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica

    Grace GmbH · Expires Oct 27, 2042

    granted
  5. US 11478424

    Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica

    Grace GmbH · Expires Oct 20, 2042

    granted
  6. US 11478420

    Vaginal probiotic products and related processes

    Grace Procurements LLC · Expires Oct 20, 2042

    granted
  7. US 11291672

    Betamethasone oral spray formulation and method of use to treat ataxia

    GRACE THERAPEUTICS INC. · Expires Mar 31, 2042

    granted
  8. US 11052029

    Cation compatible metal oxides and oral care compositions containing the metal oxides

    W.R. Grace & Co.-Conn. · Expires Jul 1, 2041

    granted

Frequently asked questions

What is US patent 10793543?

US 10793543 (Selective C-KIT kinase inhibitor) is held by HEFEI GRACEVO BIO-MEDICINE CO., LTD. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10793543?

HEFEI GRACEVO BIO-MEDICINE CO., LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.

When does US 10793543 expire?

Our index shows an expiration date of Oct 1, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.